1227 related articles for article (PubMed ID: 19124424)
1. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
3. Blocking the renin-angiotensin system: dual- versus mono-therapy.
Ravandi A; Teo KK
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):667-74. PubMed ID: 19505282
[TBL] [Abstract][Full Text] [Related]
4. Recent changes in the landscape of combination RAS blockade.
Epstein BJ; Smith SM; Choksi R
Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1373-84. PubMed ID: 19900020
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
6. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan in high-risk cardiovascular patients.
Weber MA
Am J Cardiol; 2010 Jan; 105(1 Suppl):36A-43A. PubMed ID: 20102972
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
Vijan SG
J Indian Med Assoc; 2009 Mar; 107(3):178-82. PubMed ID: 19810392
[TBL] [Abstract][Full Text] [Related]
9. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Weber MA
Am J Cardiol; 2007 Aug; 100(3A):45J-52J. PubMed ID: 17666198
[TBL] [Abstract][Full Text] [Related]
10. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
11. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
12. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
Baumhäkel M; Böhm M
Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
[TBL] [Abstract][Full Text] [Related]
13. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme.
Ruilope LM; Redón J; Schmieder R
Vasc Health Risk Manag; 2007; 3(1):1-9. PubMed ID: 17583170
[TBL] [Abstract][Full Text] [Related]
15. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
16. From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Böhm M; Baumhäkel M; Mahfoud F; Werner C
Cardiology; 2010; 117(3):163-73. PubMed ID: 21051889
[TBL] [Abstract][Full Text] [Related]
17. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
Kolasinska-Malkowska K; Filipiak KJ; Gwizdala A; Tykarski A
Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):759-71. PubMed ID: 18510491
[TBL] [Abstract][Full Text] [Related]
18. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.
Yusuf S
Am J Cardiol; 2002 Jan; 89(2A):18A-25A; discussion 25A-26A. PubMed ID: 11835907
[TBL] [Abstract][Full Text] [Related]
19. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.
Werner C; Baumhäkel M; Teo KK; Schmieder R; Mann J; Unger T; Yusuf S; Böhm M
Clin Res Cardiol; 2008 Jul; 97(7):418-31. PubMed ID: 18454336
[TBL] [Abstract][Full Text] [Related]
20. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
